Companies Dominating the Neurotrophins Landscape
- Genentech, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Regeneron Pharmaceuticals, Inc.
- Biogen Inc.
- Amgen Inc.
- Eli Lilly and Company
- Novartis International AG
- Pfizer Inc.
- Roche Holding AG
- Johnson & Johnson
- AbbVie Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Regeneron acquired Checkmate Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, for USD 1.1 billion. The acquisition added several new immunotherapy candidates to Regeneron's pipeline, including CMP-001, a bispecific antibody that targets PD-1 and LAG-3, and CMP-002, a T cell engager that targets BCMA.
- Regeneron merged its wholly owned subsidiary Regeneron Genetics Center LLC, a US-based genetic testing company, with Myriad Genetics, Inc., a US-based genetic testing company. The merger created a leading genetic testing company with a comprehensive portfolio of tests for a wide range of genetic diseases.
